Corvus Pharmaceuticals, Inc.
Corvus Pharmaceuticals, Inc. (Nasdaq: CRVS) is a clinical-stage biopharmaceutical company developing therapies that target proteins involved in immune-cell maturation and function for cancer, inflammatory diseases and other immune-mediated conditions. Its lead candidate, soquelitinib, is an oral inhibitor of ITK being… From the company’s description.
In fiscal 2025, Corvus Pharmaceuticals, Inc. reported a net loss of $15.28M. Operations used $32.80M in cash.
Margins and return on equity change in ; everything else in percent. Fewer shares and less debt are shown plainly, not as bad news — it depends what you make of buybacks. Dotted labels explain each measure. is shown separately from the annual figures.
What Corvus Pharmaceuticals, Inc. does
In the company’s own words
Corvus Pharmaceuticals, Inc. (Nasdaq: CRVS) is a clinical-stage biopharmaceutical company developing therapies that target proteins involved in immune-cell maturation and function for cancer, inflammatory diseases and other immune-mediated conditions. Its lead candidate, soquelitinib, is an oral inhibitor of ITK being studied for relapsed or refractory peripheral T-cell lymphoma and atopic dermatitis; the company is also evaluating ciforadenant, an adenosine A2A receptor antagonist, in metastatic renal cell cancer, and developing mupadolimab, an antibody targeting CD73, for potential cancer applications. Corvus has one reportable business focused on discovering and developing immunotherapies, rather than revenue-generating commercial product segments. Its clinical programs include a Phase 3 trial of soquelitinib in T-cell lymphoma and clinical studies of its other candidates; it relies on third parties to manufacture products for clinical testing. The company’s reported pipeline spans cancer and immune-mediated diseases, and it holds worldwide rights to its ITK inhibitor programs except in Greater China. Its website is https://www.corvuspharma.com/.
Company details
- Sector
- Health Care
- Industry (SIC)
- Pharmaceutical Preparations
- Headquarters
- SOUTH SAN FRANCISCO, CA
- Fiscal year end
- December
- CIK
- 1626971
- SIC
- 2834
Financial performance, year by year
Fiscal 2016–2025 · USDThe full income statement, balance sheet and cash flow for each of these years — every figure traceable to its filing — is on the Financials tab with a free account.
Who owns Corvus Pharmaceuticals, Inc. — and what changed
Funds as of 2026Q2 · superinvestors as of 2026-06-30
Largest fund holders · Corvus Pharmaceuticals, Inc.’s weight in each
Fund ownership is a floor, not a census — pensions, insurers and people holding shares directly are not visible here.
Fund ownership counts N-PORT filers only, so it is a floor rather than a census — pensions, insurers and direct holders are not visible here, and the remainder is not “held by individuals”.
Every fund and institutional holder, quarter by quarter, is on the Ownership tab with a free account.
Recent filings
All filings →Each filing opens into its own statements and disclosures here.
Put this business in context.
Compare this company with peers, find it in your funds and follow its financial history with your connected AI:
- “How do Corvus Pharmaceuticals, Inc. and its peers compare on margins and cash generation over ten years?”
- “Where did five years of Corvus Pharmaceuticals, Inc.'s earnings go — cash, debt, buybacks, reinvestment?”
- “What changed in Corvus Pharmaceuticals, Inc.'s last four quarterly filings that the numbers alone won't show?”